ReviewExpert opinion on therapeutic patents2011
Carboxylesterase inhibitors.
Review in Expert opinion on therapeutic patents, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 110 citations in OpenAlex.
- Effects of dexamethasone coadministered with oseltamivir on the pharmacokinetics of oseltamivir in healthy volunteers.Drug design, development and therapy · 2017Trial
- CES1P1 variant -816A>C is not associated with hepatic carboxylesterase 1 expression and activity or antihypertensive effect of trandolapril.European journal of clinical pharmacology · 2016Trial
- Food-Derived Natural Compounds as Molecular Targets in Cancer Prevention.Pharmaceutics · 2026Review
- Could Mussel Populations Be Differentially Threatened by the Presence of Microplastics and Related Chemicals?Toxics · 2025Article
- BENOXACOR IS ENANTIOSELECTIVELY METABOLIZED BY MICROSOMES AND CYTOSOL FROM THE HUMAN LIVER.Emerging contaminants · 2023Article
- Wide substrate range for a candidate bioremediation enzyme isolated from Nocardioides sp. strain SG-4 G.FEMS microbiology letters · 2023Article
- Powerful Potential of Polyfluoroalkyl-Containing 4-Arylhydrazinylidenepyrazol-3-ones for Pharmaceuticals.Molecules (Basel, Switzerland) · 2022Article
- Bioactivation and detoxification of organophosphorus pesticides in freshwater planarians shares similarities with humans.Archives of toxicology · 2022Article
- Conjugates of Methylene Blue with Cycloalkaneindoles as New Multifunctional Agents for Potential Treatment of Neurodegenerative Disease.International journal of molecular sciences · 2022Article
- Mouse Pharmacokinetics and In Vitro Metabolism of SH-11037 and SH-11008, Synthetic Homoisoflavonoids for Retinal Neovascularization.Pharmaceutics · 2022Article
- Comparison of Experimental Strategies to Study l-Type Amino Acid Transporter 1 (LAT1) Utilization by Ligands.Molecules (Basel, Switzerland) · 2021Article
- ADME and Pharmacokinetic Properties of Remdesivir: Its Drug Interaction Potential.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Chemoproteomics-Enabled De Novo Discovery of Photoswitchable Carboxylesterase Inhibitors for Optically Controlled Drug Metabolism.Angewandte Chemie (International ed. in English) · 2021Article
- Benoxacor is enantioselectively metabolized by rat liver subcellular fractions.Chemico-biological interactions · 2020Article
- Epithelial delamination is protective during pharmaceutical-induced enteropathy.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Anticholinesterase and Antioxidant Activity of New Binary Conjugates of γ-Carbolines.Doklady. Biochemistry and biophysics · 2019Article
- Conjugates of methylene blue with γ-carboline derivatives as new multifunctional agents for the treatment of neurodegenerative diseases.Scientific reports · 2019Article
- Ex vivo real-time monitoring of volatile metabolites resulting from nasal odorant metabolism.Scientific reports · 2019Article
- The Impact of Carboxylesterases in Drug Metabolism and Pharmacokinetics.Current drug metabolism · 2019Review
- Evaluation of human primary intestinal monolayers for drug metabolizing capabilities.Journal of biological engineering · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
introductionCarboxylesterases play major roles in the hydrolysis of numerous therapeutically active compounds. This is, in part, due to the prevalence of the ester moiety in these small molecules. However, the impact these enzymes may play on drug stability and pharmacokinetics is rarely considered prior to molecule development. Therefore, the application of selective inhibitors of this class of proteins may have utility in modulating the metabolism, distribution and toxicity of agents that are subjected to enzyme hydrolysis. AREAS COVERED: This review details the development of all such compounds dating back to 1986, but principally focuses on the very recent identification of selective human carboxylesterases inhibitors. EXPERT OPINION: The implementation of carboxylesterase inhibitors may significantly revolutionize drug discovery. Such molecules may allow for improved efficacy of compounds inactivated by this class of enzymes and/or reduce the toxicity of agents that are activated by these proteins. Furthermore, since lack of carboxylesterase activity appears to have no obvious biological consequence, these compounds could be applied in combination with virtually any esterified drug. Therefore, inhibitors of these proteins may have utility in altering drug hydrolysis and distribution in vivo. The characteristics, chemical and biological properties and potential uses of such agents are discussed here.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.